Skip to main content

Table 1 Characteristics of the study subjects

From: Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

Variable N = 450
Age (years) 60 (50–66)
Gender (% men) 51.3
BMI (Kg/m2) 30.0 (26.9–35.0)
SBP(mmHg) 135 (125–149)
DBP (mmHg) 80 (72–86)
AD (%) 32.1
MetS (%) 78.1
Obesity (%) 50.6
T2DM (%) 72.0
Cholesterol (mmol/L) 5.20 (4.54–6.19)
Triglycerides (mmol/L) 1.54 (0.99–2.45)
LDL-C (mmol/L) 3.27 (2.55–4.07)
HDL-C (mmol/L) 1.40 (1.21–1.62)
Glucose (mg/dL) 128.5 (101.3–164.9)
Apo B100 (mg/dL) 101.0 (84.0–120.0)
Apo A1 (mg/dL) 137.9 ± 14.9
CETP activity (nmol/L per h) 11.6 (10.2–13.3)
LCAT activity (470/390 nm) 2.14 (2.07–2.24)
PCSK9 (ng/mL) 319.9 (254.4–403.9)
PCSK9 rs11591147 GG 94.8
Genotypea, (%) GT 5.2
Lp particle number
 VLDL (nmol/L) 49.7 (28.5–97.8)
  Large VLDL (nmol/L) 1.83 (1.01–2.99)
  Medium VLDL (nmol/L) 7.87 (4.52–13.6)
  Small VLDL (nmol/L) 39.9 (22.7–82.2)
 LDL (nmol/L) 892.3 (681.8–1175.8)
  Large LDL (nmol/L) 113.4 (87.0–149.4)
  Medium LDL (nmol/L) 319.4 (234.3–417.2)
  Small LDL (nmol/L) 463.5 (337.9–618.5)
 HDL (µL/L) 25.3 (21.6–29.4)
  Large HDL (µL/L) 0.15 (0.11–0.19)
  Medium HDL (µL/L) 6.94 (5.08–9.21)
  Small HDL (µL/L) 17.9 (15.5–20.9)
Lp size (diameter, nm)
 VLDL 42.6 ± 0.57
 LDL 21.0 (20.9–21.1)
 HDL 8.19 (8.12–8.24)
  1. The data are presented as the mean ± SD for normally distributed data, the median (IQR) for non-normally distributed data or as the percentage for categorical variables
  2. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, AD atherogenic dyslipidemia, MetS metabolic syndrome, T2DM type 2 diabetes mellitus, LDL-C LDL cholesterol, HDL-C HDL cholesterol
  3. aSNP analysis was performed in 425 individuals